CONFIDENTIAL TREATMENT REQUESTED First Amendment to the Research and Development Collaboration and License Agreement
Exhibit 10.1
First Amendment to the
Research and Development Collaboration and License Agreement
This is the first Amendment (hereinafter “Amendment”) to the Research and Development Collaboration and License Agreement between Bayer Pharma AG, a company formed under the laws of Germany, having a place of business at Xxxxxxxxxxxxxx 000, 00000 Xxxxxx, Xxxxxxx (hereinafter: “BAYER”) and Compugen Ltd, a company formed under the laws of Israel, having a place of business at 00 Xxxxxxx Xxxxx Xxxxxx, Xxx Xxxx 00000, Xxxxxx (hereinafter: “Compugen”) effective as of 5 August 2013 (hereinafter: the “Agreement”).
WHEREAS The parties wish to amend the exhibit specifying the Bayer Development Process.
NOW THEREFORE IT IS AGREED AS FOLLOWS:
| 1. | The parties agree to replace Exhibit 1.3 of the Agreement by Exhibit 1.3 attached to this Amendment, describing the “Bayer Development Process”. |
| 2. | This Amendment shall become retroactively effective as of 5 August 2013. |
| 3. | All capitalized terms used herein shall have the meaning set forth in the Agreement. Except as expressly amended pursuant to this Amendment, all other terms and conditions of the Agreement shall remain in force unchanged and apply to this Amendment. |
Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed
separately with the Securities and Exchange Commission pursuant to the Registrant’s
application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.
|
SIGNED for and on behalf of
Bayer Pharma AG
|
SIGNED for and on behalf of
|
|
Date: February 3, 2014
|
Date: February 5, 2014
|
|
___________________________
ppa.
|
/s/ Xxxx Xxxxx-Xxxxx
President and CEO
|
|
___________________________
i.V. |
Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed
separately with the Securities and Exchange Commission pursuant to the Registrant’s
application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.
2
Exhibit 1.3: Bayer Development Process
[***, 3 pages]
Portions of the exhibit, indicated by the xxxx “[***],” were omitted and have been filed
separately with the Securities and Exchange Commission pursuant to the Registrant’s
application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange
Act of 1934, as amended.
3
